Led by Section 32 and Sanofi Ventures, funding will enable Nucleai to expand its commercial footprint in biopharma and further develop its state-of-the-art spatial biology platform TEL AVIV, Israel--(BUSINESS WIRE)--Nucleai, an AI-powered...